BioCryst Pharmaceuticals Inc. stocks have been trading up by 9.03 percent following upbeat news on its drug pipeline progress.
Click Here for a Millionaire's POV on Trading BCRX
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Citizens boosted its price target on BCRX to $28 from $25 and reaffirmed an Outperform rating, leaning on steady Orladeyo demand, reaffirmed 2026 guidance, and pipeline upside.
- The company signed a European navenibart deal with Neopharmed Gentili’s Irish affiliate worth $70M upfront, up to $275M in milestones, plus 18%–30% tiered royalties.
- Management reiterated 2026 revenue guidance of $635M–$660M, mostly powered by ORLADEYO and supported by RAPIVAB, while keeping operating expense targets intact.
- Q1 revenue beat expectations but a one‑time, non‑cash IPR&D charge drove a huge GAAP loss and a reported EPS of -$2.98, pressuring BCRX premarket.
- Despite a roughly 3.7% premarket drop after earnings, BCRX highlighted ongoing Orladeyo growth and progress in rare‑disease pipeline assets, including navenibart and BCX17725.
Live Update At 14:04:06 EDT: On Wednesday, May 13, 2026 BioCryst Pharmaceuticals Inc. stock [NASDAQ: BCRX] is trending up by 9.03%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
BCRX has quietly been grinding higher. Over the past few weeks, BioCryst Pharmaceuticals Inc. has mostly held the $8.50–$9.50 range, then pushed toward the high end as the latest news cluster hit. The most recent close around $9.595 shows buyers willing to step in on dips, even after headline noise around a big reported loss.
On the daily chart, BCRX has put in a series of higher lows from late April through mid‑May, signaling steady accumulation rather than panic selling. Intraday, the 5‑minute tape shows a stair‑step climb from the $8.70s at the open toward the $9.60 area, with shallow pullbacks and quick rebounds. That’s classic trend‑day behavior, the kind of action momentum traders love.
Fundamentals back up that interest. BCRX generated about $874.8M in revenue over the trailing period, with revenue growth running hot versus the last three and five years. A price‑to‑sales ratio near 2.5 and a P/E around 7.1 suggest the market is not paying growth‑stock multiples for BioCryst despite those trajectories. Cash metrics show a current ratio above 2, signaling BCRX can cover near‑term obligations while still funding its rare‑disease pipeline.
More Breaking News
- AAOI Stock Rockets As Analysts Hike AI-Driven Price Targets
- NOVT Stock Jumps As Earnings Beat Fuels Growth Story
- MARA Stock Wobbles As Q1 Loss Widens And Revenue Misses
- AMBQ Stock Breaks Out As Traders Hunt Volatility
For active traders, that combination of improving chart structure and solid medium‑term guidance keeps BCRX squarely on the watchlist.
Why Traders Are Watching BCRX Right Now
BCRX is getting fresh attention after a string of catalysts that line up almost perfectly for momentum‑focused trading. First, Citizens raised its price target to $28 and reaffirmed an Outperform rating. That’s not a small bump for BioCryst Pharmaceuticals Inc. when the stock is still under $10. The call leans on steady Orladeyo patient starts, reaffirmed 2026 revenue guidance, and visible upside from navenibart and BCX17725. For traders, that’s a clear signal a major bank sees room for upside, even after recent volatility.
At the same time, BCRX locked in a serious non‑dilutive funding deal. The company licensed European rights to its hereditary angioedema candidate navenibart to Neopharmed Gentili’s Irish affiliate. Terms are strong: $70M upfront, up to $275M in milestones, plus 18%–30% tiered royalties. That kind of structure validates the drug’s commercial potential and shores up the balance sheet without dumping new shares on the market. Traders who care about dilution risk should pay attention here.
The earnings print looked ugly on the surface. BCRX swung from breakeven to a massive GAAP net loss of about $721.8M in Q1 and reported EPS of -$2.98, well below consensus. Shares traded down roughly 3.7% premarket on 2026/05/06. But most of that hit came from a one‑time, non‑cash IPR&D charge, not a collapse in the core business. Revenue modestly beat expectations, Orladeyo continued to grow, and BCRX reaffirmed 2026 revenue guidance of $635M–$660M with operating expenses still pegged at $450M–$470M.
For traders, that split between scary headlines and more stable underlying trends is exactly where opportunity often shows up.
Conclusion
BCRX is a classic case of short‑term pain versus long‑term narrative. On one side, BioCryst Pharmaceuticals Inc. just posted a huge reported loss and took a hit in early trading, which scared out some weak hands. On the other, the company reaffirmed 2026 revenue guidance, kept its expense outlook steady, and secured a rich European partnership for navenibart that brings in cash now and potential royalties later. Add an analyst price‑target hike to $28 with an Outperform rating, and you have a setup that many traders will not ignore.
The charts support that story. BCRX is grinding higher off its late‑April base, with intraday action showing controlled dips and strong bids underneath. That tells you real money is stepping in on red days, not running for the exits. At the same time, BioCryst Pharmaceuticals Inc. still carries real risk: negative equity, a complicated P&L, and reliance on a concentrated rare‑disease portfolio. None of this is a sure thing, and every trader has to do their own homework. As Tim Bohen, lead trainer with StocksToTrade says, “A good trade setup checks all the boxes—volume, trend, catalyst. Don’t trade if you’re missing pieces of the puzzle.” In the case of BCRX, that means weighing the technical action against the fundamental story and the headline flow before committing capital.
As Tim Sykes loves to remind his students, “The market doesn’t care about your opinion, only your preparation.” For BCRX, that preparation means studying the catalysts, understanding that the big loss was mostly non‑cash, tracking Orladeyo and navenibart data, and watching the price action in real time. This article is for educational and research purposes only, but for disciplined traders who cut losses fast and respect the risks, BioCryst Pharmaceuticals Inc. remains a name worth monitoring closely.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.